SCHEMBL4396800

SCHEMBL4396800

Cc1ccc(C(=O)Nc2ccc3c(C(=O)NC(C)C)nn(CC(F)(F)F)c3n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
MLYCD O95822 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ADORA3 P0DMS8 4/20 0.38
ADORA2A P29274 4/20 0.38
ADORA1 P30542 3/20 0.38
P2RY14 Q15391 3/20 0.38
POLB P06746 1/20 0.38
RET P07949 1/20 0.37
FPR1 P21462 1/20 0.37
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4392995 0.86 ROCK2 (0.44) RAB9ANPC1KMT2AADORA2A
SCHEMBL4398483 0.86 NPC1 (0.42) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL4396840 0.86 P2RY14 (0.48) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL4394568 0.85 HTR3A (0.42) RAB9ANPC1MEN1KMT2AP2RY14
SCHEMBL3961436 0.82 RAB9A (0.42) RAB9ANPC1MLYCDKDM4EMEN1
SCHEMBL4400654 0.79 SMN1; SMN2 (0.41) RAB9ANPC1MEN1KMT2AADORA2A
SCHEMBL4793179 0.76 ROCK2 (0.41) MEN1KMT2AADORA2ALMNAMAPT
SCHEMBL4393075 0.74 KDM4E (0.42) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL4401713 0.74 GRM5 (0.39) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL4399226 0.74 NAMPT (0.41) RAB9ANPC1KDM4EKMT2AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306100-A1 METHODS OF TREATING SCHIZOPHRENIA LEXICON PHARMACEUTICALS, INC. 2009-12-10 US disclosed
US-20080153811-A1 methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. LEXICON PHARMACEUTICALS, INC. 2008-06-26 US disclosed
US-20070049608-A1 Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use LEXICON PHARMACEUTICALS, INC. 2007-03-01 US disclosed
US-20060258691-A1 Methods and compositions for improving cognition LEXICON PHARMACEUTICALS, INC. 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153811-A1 methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. CHAT, PSEN2, PSEN1 RAB9A 1214/4885NPC1 76/4885MLYCD 3069/4885
US-20090306100-A1 METHODS OF TREATING SCHIZOPHRENIA CHAT, GAP43, GRIN2A RAB9A 1054/4885NPC1 308/4885MLYCD 3830/4885
US-20060258691-A1 Methods and compositions for improving cognition PSEN1, PSEN2, APP RAB9A 808/4885NPC1 256/4885MLYCD 1673/4885
US-20070049608-A1 Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use DPYD, TYMP, PNKP RAB9A 2588/4885NPC1 3748/4885MLYCD 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.